Rede D'Or São Luiz (RDOR3) Q2 2026 earnings summary

Executive summary

• Achieved record gross revenue of R$9.9 billion in Q2 2026, up 9.9% year-over-year, with strong growth in surgeries and oncology services.

• Net income rose 9.7% year-over-year to R$1.2 billion, with EBITDA up 18.2% to R$2.9 billion and margin improvement.

• SulAmérica portfolio saw record growth in dental and healthcare beneficiaries, with improved consolidated loss ratios and profitability.

• Company recognized for sustainability and quality, with multiple international awards for hospital excellence.

• Operations span hospital services, insurance, private pension, and asset management, with 76 hospitals and over 10,000 beds.

Financial highlights

• Consolidated gross revenue for the group was R$16.0 billion in Q2 2026, up 5.9% year-over-year; six-month revenue at R$29.0 billion, up from R$26.9 billion year-over-year.

• Oncology gross revenue in Q2 2026 was R$1.149 billion, up 22.3% year-over-year; six-month oncology revenue at R$2.2 billion, up 23%.

• SulAmérica net revenue grew 6.9% year-over-year to R$8.7 billion, with EBITDA up 53.4% to R$612.1 million.

• Gross profit rose 20.1% year-over-year to R$2.3 billion, with gross margin expanding by 2.3 percentage points.

• Cash flow for the semester was R$5.4 billion, representing a 92.2% EBITDA conversion rate.

Outlook and guidance

• Focus remains on operational efficiency, margin improvement, and sustainable growth across all segments, with over 20 expansion projects expected to deliver 2,690 new beds between 2026 and 2028.

• Continued expansion in oncology and high-occupancy hospitals, with disciplined capital allocation for organic and inorganic growth.

• No explicit forward-looking financial guidance provided; management emphasizes long-term value creation and sector sustainability.